Denmark Blocks Use of AstraZeneca COVID-19 Adenovirus Vector Vaccine Over Blood Clots
Soeren Brostroem, director of the National Board of Health (L) and Tanja Erichsen, from Danish Medicins Agency announced the suspension of the AstraZeneca adenovirus vector variant from distribution in Denmark. Erichsen fainted during the conference and was rushed to hospital. (Image: MADS CLAUS RASMUSSEN/Ritzau Scanpix/AFP via Getty Images)
Denmark announced it is permanently halting the use of AstraZeneca’s COVID-19 vaccine in its country’s vaccination campaign, becoming the first nation to completely halt usage of the brand. The decision followed confirmation by Danish health authorities that the company’s adenovirus vector was linked to severe cases of blood clotting, with one case resulting in death of the recipient.